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Background. Organs procured from deceased donors em-
anate from individuals with diverse genetic backgrounds. Donor
organs, therefore, may vary in their response to injury and im-
mune stimuli in a genetically determined manner. We assessed
polymorphisms from 244 renal allograft donors to better under-
stand the impact of donor polymorphisms on selected transplant
outcomes.
Methods. Donor genomic DNA restriction fragment length
polymorphisms were assayed for evidence of common cytokine
[interleukin (IL)-2, IL-6, IL-10, tumor necrosis factor (TNF)-a,
TGF-b , interferon (IFN)-c] and chemokine (CCR2, CCR5)
polymorphisms. Associations between donor polymorphisms
and graft events were determined using chi-square, linear re-
gression, and Kaplan-Meier analyses.
Results. Several genotypic polymorphisms demonstrated a
modest association with acute rejection, including the trans-
forming growth factor (TGF)-b T/C codon 10 (P = 0.027)
and the CCR5 G/A 59029 (P = 0.039) genes by chi-square
analysis. Notably, the presence of the T allele in the IFN-c
gene (+874) demonstrated a highly significant association with
biopsy-proven chronic allograft nephropathy (P < 0.008). This
association remained highly significant in a multiple linear re-
gression model that incorporated biopsy-proven acute rejection
as a covariate.
Conclusion. These data suggest that many of the donor poly-
morphisms studied in this analysis may influence a recipient’s
immune response to a renal allograft. However, their greatest
impact may be demonstrated in long-term outcomes.
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The genetic regulation of cytokine and chemokine gene
expression is increasingly recognized as a significant vari-
able affecting allograft outcome. Significant interindivid-
ual variations exist in many of the genes that regulate
these molecules. This variation can be attributed, in part,
to single nucleotide polymorphisms (SNPs) in the pro-
moter region of a gene affecting the amount or rate of
protein production, or the presence of variable number
tandem repeats that can also alter the genetic regulation
of a particular protein.
Investigations of genetic polymorphisms in solid or-
gan transplantation have primarily dealt with recipient
cytokine polymorphisms. Hutchinson et al studied tu-
mor necrosis factor (TNF)-a and interleukin (IL)-10 gene
polymorphisms in heart, liver, kidney, and simultaneous
pancreas-kidney transplant recipients, and determined
that a G/A polymorphism at position −308 in the recipi-
ents’ TNF-a promoter was associated with an increased
rate of rejection and an increased rate of steroid-resistant
rejection in kidney transplant recipients [1, 2]. Poli et al
demonstrated similar associations [3]. However, not all
studies demonstrate such a clear relationship between
genetic polymorphisms and outcomes. Marshall et al [4]
were unable to delineate a significant contribution of a
number of cytokine SNPs to the incidence or severity of
acute rejection in a cohort of kidney transplant recipients.
These somewhat contradictory findings highlight the
fact that the recipient genome has yet to yield a signature
pattern of polymorphisms or genetic profile that defines
transplant risk. This has spawned interest in examining
the other half of the transplant puzzle, the donor organ.
Many relevant immune responses, particularly effector
responses, take place in the donor organ, a microenvi-
ronment that is often highly disparate from the recipient’s
own tissues. Our present understanding of organ-specific
function now suggests that these tissues may play a
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significant role in regulating immune responses, and their
response to injury may vary considerably from one indi-
vidual to another. Kidney tubular epithelial cells, for in-
stance, express cytokines, chemokines, and many of their
respective receptors in response to injury, many of which
have both been implicated in acute rejection and shown
to have polymorphic expression [5–9].
Specific cytokines that influence the complex molecu-
lar and cellular biology may play different roles in the
context of transplant rejection and chronic allograft dys-
function. For instance, TNF-a may be very significant
in the context of acute rejection; whereas transforming
growth factor-beta (TGF-b) may play a more prominent
role in chronic allograft dysfunction, although its poten-
tial involvement potentially in acute rejection is not to
be discounted [10–12]. Chemokines also certainly play
an important role in transplant rejection [13, 14]. Thus,
any genomic examination of these transplant events must
consider multiple genes in each family simultaneously.
Donor cytokine polymorphisms have recently been as-
sociated with delayed graft function [15], acute rejection
[16], and reduced allograft survival [17]. We undertook
this analysis to expand upon these initial studies by assess-
ing the effects of combinations of polymorphisms on allo-
graft events: acute rejection, chronic allograft nephropa-
thy, and graft survival.
METHODS
Study type and DNA extraction
This was a case-cohort analysis, nonrandomized study
examining donor samples. This study was approved by
the appropriate University of Wisconsin and the National
Institutes of Health (NIH) Institutional Review Boards.
Donor splenocytes, obtained from the University of Wis-
consin Histocompatibility laboratory or venous blood
from living donors was collected in 5-mL EDTA-treated
tubes prior to analysis. A subset of recipients of these or-
gans (N = 68) also provided venous blood collected as
above. This represented the set of recipients contacted
who would provide informed consent at time of follow-
up. DNA was isolated using the Puregene DNA Isolation
Kit (Gentra Systems, Minneapolis, MN, USA) according
to the manufacturer’s instructions.
Donor and recipient samples were obtained from a sin-
gle institution (UW). All donor samples were obtained
from the 1997 to 1999 donor cohort at the institution.
Allograft function
Allograft biopsies were taken from recipients who re-
ceived induction therapy utilizing depletion antibodies
(rabbit antithymocyte globulin, Thymoglobulin; Gen-
zyme, Cambridge, MA, USA) or monoclonal CD25-
specific antibodies (basiliximab or daclizumab) followed
by maintenance immunosuppression with a calcineurin
inhibitor (cyclosporine A or tacrolimus), mycophenolate
mofetil, and/or prednisone. Target cyclosporine A levels
were 150 to 200 ng/mL during the first year after trans-
plantation. Target tacrolimus levels were 5 to 12 ng/mL
during the first year after transplantation. Treatment was
delivered with calcineurin inhibitors independent from
this study and in keeping with standard of care. Biopsies
were obtained from the renal cortex using a 16-gauge
needle core biopsy device.
Individuals with increased serum creatinine (Scr) lev-
els ≥0.3 mg/dL above baseline without another cause of
graft dysfunction (e.g., urinary tract infection, obstructive
uropathy, or individuals with proteinuria >1 g per day)
underwent percutaneous graft biopsy. If rejection was
present on the biopsy, individuals were treated originally
with bolus corticosteroids (500 mg methylprednisolone)
for three days then a corticosteroid taper. If the Scr or
beta2-microglobulin level did not improve during that
72-hour period, rabbit antithymocyte globulin (Thy-
moglobulin was added to the regimen at 1.5 mg/kg for
3 to 7 days). If chronic allograft nephropathy (CAN) was
diagnosed by biopsy, the most common first step in man-
agement was a dose reduction in calcineurin inhibition.
All biopsies were reviewed by pathologists using Banff
criteria independent of the polymorphism analysis [11].
Characterization and detection of cytokine
polymorphisms
All polymorphisms were determined by allele-specific
polymerase chain reaction (PCR) with subsequent al-
lele or genotype determination using methodologies
from commercially available kits or restriction fragment
length polymorphism (RFLP) analyses. Cytokine geno-
types (IL-6, IL-10, TNF-a, TGF-b , and IFN-c) were as-
sessed using the One Lambda, Inc., Genotyping Kit (One
Lambda, Inc., Canoga Park, CA, USA) [18]. Polymorphic
differences in the IL-2 gene were determined following
restriction enzyme digestion as described [18].
Characterization and detection of chemokine
polymorphisms
CCR5-32, CCR5-59029, and CCR2-V64I genotype.
The CCR5-32 genotype was determined by sizing PCR
amplicons that include the entire region of the dele-
tion [19]. PCR was performed using 50 ng of genomic
DNA in a reaction mix that contained 1× Taq polymerase
buffer (Applied Biosystems, Inc., Foster City, CA, USA),
0.2 mmol/L dNTP, 150 ng each primer and 0.2 U of Taq
Polymerase (Applied Biosystems, Inc.). Thermocycling
(PTC 100; MJ Research, Watertown, MA, USA) con-
sisted of initial denaturation at 94◦C for 4 minutes fol-
lowed by 35 cycles of 94◦C for 30 seconds, 52◦C for 45
seconds, and 72◦C for 1 minute, and final extension at
72◦C for 7 minutes. Amplicons were visualized under UV
light on 2% agarose gel containing ethidium bromide. The
sense primer was 5′-TGTTTGCGTCTCTCCCAG-3′,
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and antisense was 5′-CACAGCCCTGTGCCTCTT-3′.
These primers yield a 233 and 201 bp product for the
wild-type and deletion amplicons, respectively.
CCR5–59029 and CCR2-V64I genomic variants were
detected using PCR conditions identical to those for
CCR5-32, except for an annealing temperature of 65◦C.
Sense, 5′-CCCGTGAGCCCATAGTTAAAACTC-3′,
and antisense, 5′-TCACAGGGCTTTTCAACAGTAAG
G-3′, primers were used for PCR for CCR5-59029 ge-
nomic variants. This reaction yielded a 268-bp amplicon.
The PCR product was digested with 10 units of Bsp1286I
(New England BioLabs, Beverly, MA, USA). Amplicons
from individuals homozygous for 52909-G appear as a
single ∼130-bp band after Bsp1286I digestion. Individ-
uals homozygous for 59029-A have a 258-bp product,
while heterozygotes display both bands.
The sense primer for the CCR2-V64I genotype was
5′-TTGGTTTTGTGGGCAACA TGATGG-3′, and the
antisense primer was 5′-CATTGCATTCCCAAAGACC
CACTC-3′. Amplification of the PCR product resulted
in a 173-bp product. An A at nucleotide position 190
encodes isoleucine at position 64 and yields restriction
fragments of 149 and 24 bp after BsaBI digestion. In con-
trast, the 173-bp amplicon remains uncut if a G encoding
a valine is present.
Statistical analysis
Donor samples were genotyped. Graft events, biopsy-
proven acute cellular rejection; biopsy-proven CAN, and
graft loss defined as return to dialysis or retransplanta-
tion, were obtained from the transplant center database.
If a donor organ was associated with any of these events,
it was tabulated as that for the donor, regardless of the
outcome of the other kidney. Each polymorphism was
tested for Hardy-Weinberg equilibrium via a two degree-
of-freedom chi-square goodness of fit. The transplant
outcome measures were cross-tabulated against the phe-
notype derived from each polymorphic genotype. Trans-
plant outcome measures (e.g., rejection), were then tested
via Fisher exact test with Bonferroni-Holm correction.
Differences among rejectors versus nonrejectors when
comparing increased versus low phenotypes were de-
termined following 2 × 2 contingency and chi-square
analysis (JMP, SAS Institute, Cary, NC, USA). A power
calculation determined that a donor population of 200
individuals would be necessary to determine a signifi-
cant difference in the effect of homozygosity of a specific
allele based on its distribution in the population led to
a significant association (>3-fold increase in incidence)
with acute rejection, based on a historic acute rejection
rate of 38% at our institution versus heterozygosity or
homozygosity of the other allele (a = 0.05). We also
performed Kaplan-Meier estimates of time to acute re-
jection. Comparisons between groups bearing individual
Table 1. Donor and recipient demographics
Donors N 244
Average age years ± SD 39.2 ± 15.4
Gender (F/M) 103 (42%)/141 (58%)
Deceased donor/living donor 232 (95%)/12 (5%)
Cold ischemia time hours 16.2 ± 11.5
Average no. HLA mismatches 2.3 ± 2.1
Donors after cardiac death/ 39 (16%)/29 (12%)
extended criteria donors
Recipients N 379
Average age years ± SD 49.3 ± 16.7
Gender (F/M) 148 (39%)/231 (61%)
Caucasian/African-American/other 326 (86%)/45 (12%)/8 (2%)
The vast majority of the donor population was Caucasian (>90%). Twenty-one
percent of the deceased donors would be classified as extended criteria donors.
polymorphisms were evaluated using the log-rank test.
P values < 0.05 (two-sided) were considered significant.
Next, we developed a multiple linear regression model
examining acute rejection or CAN as the dependent vari-
able. We correlated any event with the donor as a sin-
gle categorization, based on the intent of the study. The
independent variables in each model were donor age,
cold ischemia time, recipient age, delayed graft function,
recipient age, gender, degree of human leukocyte anti-
gen (HLA) mismatch, depletion versus monoclonal anti-
body induction therapy, and acute rejection for the CAN
model. Predicted phenotypes defined by the aforemen-
tioned polymorphisms and genotype analyses were then
analyzed for their potential independent effects on each
event.
To investigate the interaction between genetic poly-
morphisms, and to potentially strengthen the power of
the analysis, we reduced the predicted phenotypes associ-
ated with the graft events in the aforementioned analyses
to one genetic variable [20] and reassessed the impact of
donor genomics in the model. Thus, any genotype asso-
ciated with a readily described phenotype that had an in-
dependent association with acute rejection (e.g., TGF-b ,
CCR5 59029A, or CAN) were grouped into the compos-
ite variable.
RESULTS
Demographics of the study populations
Donor demographics are summarized in Table 1. The
vast majority of the 244 donors were deceased donors
(95%) and Caucasian (91%). When possible, donor sam-
ples were genotyped for every polymorphism examined.
However, in some instances, sample volume or techni-
cal complications related to repeated assays may have
limited testing for every allelic difference examined. The
overall number of donors genotyped for each cytokine
and chemokine allelic polymorphisms examined were:
TNF-a (N = 240), TGF-b (N = 234), IFN-c (N = 239),
IL-2 (N = 244); IL-6 (N = 242), IL-10 (N = 233), CCR5
(N = 239), and CCR2 (N = 239).
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Table 2. Cytokine genotype polymorphism distribution in allograft donor population
Non- Acute
Gene Position Genotype Phenotype rejection rejection Chi-square
IL-2 −330 G/G High 6 3 NS, P = 0.25
T/G Low 48 49
T/T 82 56
IL-6 +174 G/G High 51 34 NS, P = 0.22
G/C 64 27
C/C Low 21 45
IL-10 −1082 GCC/GCC High 23 15 NS, P = 0.21
GCC/ACC 36 35
−819 GCC/ATA 29 23
ACC/ACC Low 4 6
−592 ACC/ATA 28 17
ATA/ATA 5 12
TNF-a −308 A/A High 34 39 NS, P = 0.25
G/A 74 57
G/G Low 25 11
TGF-b Codon 10 T/T G/G High 52 31 P = 0.027
T/C G/G 35 47
T/C G/C 16 14
Codon 25 C/C G/G Low 16 7
C/C G/C 4 6
C/C C/C 0 2
T/T C/C 3 1
IFN-c +875 T/T High 25 11 NS, P = 0.074
T/A 73 57
A/A Low 34 39
Cytokine gene polymorphisms and predicted phenotype distribution based on acute rejection diagnosed in the donor graft. All analyses were performed as described
in Methods.
The donor cohort was separated into groups based on
recipient transplant outcomes. Initial chi-square analyses
were performed separating the groups into nonrejecting
donors (N = 136) and donors with recipient biopsy-
proven acute rejection (N = 108). Donor and recipient
gender, age, and race/ethnicity were recorded, and indi-
vidual donors were genotyped as high or low gene protein
producers as previously established [1, 2, 12]. Observed
frequencies were not significantly different from the ex-
pected frequencies under Hardy-Weinberg equilibrium
conditions.
Adequate follow-up and outcome data were avail-
able for 379 individuals who received kidneys from these
donors at the University of Wisconsin. Individuals who
received combined organ transplants (e.g., kidney and
pancreas transplantation) were excluded from the analy-
sis. The majority of these individuals were male and Cau-
casian (Table 1).
Acute rejection
As described in Methods, we examined for potential as-
sociations between donor polymorphisms and acute re-
jection. We observed associations between select genes
and acute cellular rejection. When the donor TGF-b
alleles were separated into conglomerate genotypes,
those haplotypes linked with increased protein produc-
tion were significantly associated with grafts that mani-
fested acute cellular rejection (P = 0.027).
We also investigated select chemokines polymor-
phisms. In the context of this, one analysis examined
functional versus impaired CCR5, based on the predicted
phenotype of the genotype as opposed to simply high
or low protein production (Table 3). The CCR5 59029A
allele was more prevalent in donor kidneys that experi-
enced acute cellular rejection (P = 0.029) (Table 3). Es-
sentially the same statistical results were obtained when
only deceased donors were assessed. The donor TGF-b
haplotypes associated with increased protein production
were associated with grafts that manifested acute cellular
rejection (P = 0.023). The CCR5 59029A allele also was
linked with donor kidneys that experienced acute rejec-
tion (P = 0.027). No relationship was evident between
other allelic or donor polymorphisms tested and acute
cellular rejection.
The high-producing IFN-c T allele at +875, when ex-
pressed in donors, was also associated with a trend toward
acute rejection.
Chronic allograft nephropathy
The CCR5 59029A allele also demonstrated an associa-
tion with biopsy-proven CAN (P < 0.04). However, more
striking was the highly significant association between the
presence of the T allele associated with increased produc-
tion of IFN-c and CAN (P = 0.007) (Table 4).
Again, when only deceased donor samples were ex-
amined, the same results held (CCR5 59029A: P = 0.03;
IFN-c: P = 0.002). We observed no other significant as-
sociations between alleles, polymorphisms, or predicted
phenotype and outcomes, save for a moderate effect of
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Table 3. Chemokine genotype polymorphism distribution in allograft donor population
Gene Position Genotype Phenotype Non-rejection Acute rejection Chi-square
CCR5 +/+ Functional 102 81 NS, 0.4
+/− 32 22
−/− Impaired 1 1
CCR5 59029 G/G High 30 18 P = 0.029
G/A 75 56
A/A Low 30 30
CCR2 +190 +/+ High 109 82 NS, 0.94
+/64I 22 18
64I/64I Low 4 4
Chemokine gene polymorphisms and predicted phenotype distribution based on acute rejection diagnosed in the donor graft. All analyses were performed as
described in Methods using chi-square analyses.
Table 4. Donor allelic and genotype polymorphisms and
biopsy-proven CAN
Polymorphism P value (Fisher exact)
IL-2 –330 G NS, P = 0.16
IL-6 –174G NS, P = 0.34
IL-10 GCC NS, P = 0.91
TNF-a –308A NS, P = 0.84
TGF-b codon 10 T or codon 25 C NS, P ≥ 0.78 for each
IFN-c +875 T P = 0.0076
CCR5 (+/+) NS, P = 0.166
CCR5 59029-A P = 0.037
CCR2 +190 (+/+) NS, P = 0.79
Allelic and genotype polymorphisms in association with biopsy-proven
chronic allograft nephropathy in the donor graft. All analyses were performed
as described in Methods using Fisher exact test with Bonferroni-Holm correction.
the increased TNF-a production phenotype and graft fail-
ure (P = 0.04).
Linear regression analysis
The linear regression models attempted to take advan-
tage of variables known to affect acute rejection and CAN
and determine if donor genomics affect those events
(Table 5). The donor age range was 6 to 68 years. The
delayed graft function rate (per donor) was 31% (N =
75 donors). Fifty-three percent (N = 129) of the donor-
related kidney transplants were treated with monoclonal
antibody induction. In the acute rejection model, donor
age [relative risk (RR) 1.14; P = 0.01); delayed graft func-
tion (RR 2.1; P = 0.02); and the degree of HLA mismatch
(RR 1.78; P = 0.003) all were significantly associated
with acute rejection. The increased TGF-b production
predicted phenotype demonstrated a modest effect (RR
1.28; P = 0.019). The donor CCR5 (increased receptor
expression), low-producing IFN-c, and IL-2 phenotypes
did not manifest significant independent effects. The com-
bination phenotype variable demonstrated a moderately
significant effect on acute rejection (RR 1.22; P = 0.033).
In the CAN model, delayed graft function had a mod-
est though not significant effect on CAN (RR 1.35; NS,
P = 0.072). Donor age (RR 2.44; P = 0.001) and acute re-
jection (RR 1.47; P = 0.01) were significantly associated
with CAN. The donor CCR5 increased receptor expres-
sion phenotype did not appear to have an independent
effect. However, the increased IFN-c production pheno-
type displayed a highly significant independent effect on
the development of CAN (RR 1.73; P = 0.001). We then
re-examined the model with the combination phenotype
variable for the phenotypes associated with adverse out-
comes/function in CAN. This component variable also
demonstrated a significant independent effect on the evo-
lution of CAN (RR 1.47; P = 0.008).
Kaplan-Meier analyses
We also analyzed the alleles and polymorphisms as-
sociated with the rate of biopsy-proven acute rejection
by Kaplan-Meier methodology. Interestingly, there was a
trend in time to acute rejection in donors that manifested
the codon 10 TGF-b haplotypes associated with high lev-
els of protein production (NS, P = 0.077). There were
not any significant differences in time to acute rejection
among the other individual alleles tested.
We then examined if the presence of the codon 10
TGF-b haplotype in both donor and recipient led to
an increased rate of rejection. We compared this group
(N = 11) to the other donor/recipient combinations in ag-
gregate (+ donor/-recipient; —donor/+ recipient; and—
donor/− recipient) in terms of rate of acute rejection.
There was again a trend toward a more rapid rate of acute
rejection in the + donor/+ recipient group (P = 0.062)
(Fig. 1). A similar analysis examining time to a composite
endpoint of biopsy-proven CAN or allograft failure in +
donor/+ recipient increased IFN-c phenotype (N = 24)
versus the other categories in aggregate demonstrated a
significant difference (P = 0.01; Fig. 2). There was no sig-
nificant difference in the rate of reaching this composite
outcome point when comparing the CCR5 phenotype
combinations.
DISCUSSION
The recipient has been the focus of most of the trans-
plantation genomics studies to date. However, the conse-
quences of donor-recipient interactions occur as a result
of the net effects of both donor- and recipient-derived
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Table 5. Linear regression model: Impact of donor genomic variables on acute rejection and chronic allograft nephropathy
Acute rejection Chronic allograft nephropathy
Relative risk Relative risk
Parameter (95% CI) P value (95% CI) P value
Donor age 1.14 (1.06; 1.31) P = 0.01 2.44 (1.31; 3.34) P = 0.001
DGF 2.1 (1.3; 3.03) P = 0.02 1.35 (0.97; 1.79) NS, P = 0.074
Recipient age 1.05 (0.87; 1.95) NS 0.97 (0.89; 1.07) NS
CIT 1.57 (0.88; 1.98) NS 1.92 (0.93; 3.78) NS
Gender (M vs. F) 0.94 (0.84; 1.11) NS 1.34 (0.65; 2.31) NS
Depletion vs. monoclonal antibody 0.81 (0.67; 1.05) NS 0.89 (0.66; 2.78) NS
Degree HLA mismatch 1.78 (1.56; 1.97) P = 0.003 1.36 (0.92; 1.91) NS
↑ TGF-b phenotype 1.28 (1.07; 1.49) P = 0.019 – –
CCR5 59029A genotype (↑ receptor expression) 1.78 (0.92; 3.15) NS 1.14 (0.94; 1.26) NS
Low-producing IFN-c 1.63 (0.91; 3.43) NS – –
↑ IFN-c phenotype – – 1.73 (1.60; 1.88) P = 0.001
↑ IL-2 phenotype 1.45 (0.76; 2.36) NS – –
Composite phenotypic variable 1.22 (1.02; 1.48) P = 0.033 1.47 (1.33; 1.61) P = 0.008
Acute rejection – – 1.47 (1.26; 1.69) P = 0.01
Results of linear regression examining potential impact of predicted phenotype of alleles and polymorphisms shown to be significant in the chi-square and Fisher
exact analyses. Analyses for each model were performed as described in Methods. Genomic variables that were not significant for acute rejection or chronic allograft
nephropathy in the aforementioned analyses were not included in the model for that condition (e.g., the low-producing IFN-c phenotype was not tested in the chronic
allograft nephropathy model). A composite predicted phenotypic variable was incorporated into the model to increase its power. Acute rejection was a covariate in the
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Fig. 1. Kaplan-Meier analysis of time to biopsy-proven acute rejec-
tion. Donor/recipient pairs positive for the increased TGF-b1 produc-
ing haplotype (codon 10) had a trend toward a more rapid rate to time
to acute rejection than donor +/recipient −; donor–/recipient +; and
donor–/recipient—pairs (NS, P = 0.062).
factors, and donor tissues can vary both in their ability to
stimulate immunity and in their ability to heal after injury.
For example, early rejection episodes can be affected by
donor age and ethnicity [17, 18]. Other forms of injury
(e.g., brain death and procurement), alter intragraft cy-
tokine and adhesion molecule production, thereby set-
ting the stage for additional allograft damage [21–23].
Thus, an accurate assessment of donor-specific variables
has significant implications, especially given the increased
interest in extended-criteria donors [24]. This study sug-
gests that select donor genes could be incorporated as
donor-specific variables that influence acute rejection and
CAN, emphasizing the importance of the donor genetic
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Fig. 2. Kaplan-Meier analysis of time to composite endpoint of
biopsy-proven chronic allograft nephropathy (CAN) or graft loss.
Donor/recipient pairs positive for the IFN-c increased production phe-
notypes (based on presence of T allele) had a significantly greater rate
of reaching the composite end point than donor +/recipient −; donor–
/recipient +; and donor–/recipient pairs (P = 0.01).
The most striking finding in our study was that the al-
lele associated with increased IFN-c production in donors
significantly increased the likelihood of CAN. There is no
doubt that increased recipient IFN-c expression is asso-
ciated with chronic allograft dysfunction [25]. However,
recently the focus on this cytokine has shifted to its effect
within donors, per se [26]. Halloran et al suggested an es-
sential role for IFN-c in preventing necrosis early during
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a rejection process, but in so doing, it potentiated chronic
allograft dysfunction [26]. The latter effect certainly could
explain, in part, the data presented herein. Additionally,
for secreted proteins, the source of the molecule may be
less relevant than the absolute amount present in the in-
tragraft milieu. In this regard, both donor and recipient
contributions may be equally relevant.
The intriguing aspect about such observations is that
they suggest the donor organ may have a role in its own
fate. There are several mechanisms through which donor
grafts could credibly influence graft outcome. High ex-
pression polymorphisms could increase intragraft con-
centrations of cytokines for instance, luring increased
numbers of recipient cells to the allograft to initiate or
augment an immune response. Cytokines are not allospe-
cific, and donor-derived proinflammatory cytokines can
influence recipient-derived cells. Wong et al [27] recently
described the integral role of exogenous TGF-b1 in per-
petuating tubulitis and in enhancing CD8+ T cell pro-
liferation. Their studies suggest a mechanism by which
intragraft TGF-b1 could have a direct effect in the devel-
opment of acute rejection, akin to that described above.
We also determined TGF-b1 codon 10 “status” and
IFN-c “status” in a manner akin to that which we do clin-
ically to assess cytomegalovirus status. Individual donor
+/recipient + pairs demonstrated either a trend toward
increased rejection rates in the case of TGF-b1 codon 10,
or a significantly increased rate of graft loss or CAN in the
case of IFN-c increased production phenotype. Though
an indirect approach, these results further suggest that
donor genomics bear consideration in terms of donor se-
lection as they could influence not just the graft but po-
tentially alter donor-recipient interactions in a way that
affects graft outcomes.
Another possibility is that donor-derived passenger
mononuclear cells might express more receptor proteins.
These cells, coursing through the graft, would bind lig-
ands, initiating and exacerbating intragraft inflammation
after transplantation. In this regard, the association be-
tween donor homozygosity for the CCR5 59029-A allele
and acute rejection is of interest. This particular allele
has been linked with a reduction in acute allograft rejec-
tion in kidney transplant recipients [19], but its presence
in donors was associated with an increased risk for re-
jection. CCR5 is a member of the chemokine receptor
superfamily. A wide array of immune responses during re-
nal allotransplantation are triggered by chemokines and
chemokine receptors [28–30]. CCR5, a member of the
chemokine receptor superfamily, and its ligands (MIP-1a,
MIP-1b , and RANTES) are elevated in both subclinical
and clinical acute rejection [26]. CCR5 is expressed pre-
dominantly on dendritic cells, memory cells, and mono-
cytes, and thus, its presence on donor-derived passenger
mononuclear cells could be invoked to explain the find-
ings herein. It is also intriguing that CCR5 has been iden-
tified on vascular smooth muscle cells [31]. This raises an
alternative hypothesis, that endothelial-vascular smooth
muscle interactions in the allograft could be a site for
important CCR5 effects. Additional studies will be nec-
essary to explicitly examine the role of CCR5 on donor
cells in the setting of transplantation.
The associations between recipient polymorphisms
and transplant outcomes (e.g., acute rejection or graft
survival) have been examined in several studies [19, 32–
36]. Recent work also has demonstrated interest in the
potential association between donor polymorphisms and
transplant outcomes [16, 32, 36, 37]. Marshall et al iden-
tified an association between a polymorphism at posi-
tion –174 in the donor IL-6 gene and acute rejection in
a single-center study [16]. St. Peter et al [15] also noted
an association between polymorphisms in one of three
classes of glutathione-S-transferase in donor grafts and
delayed graft function. Finally, in another analysis, the
donor G protein b3 subunit 825T genotype was linked
with reduced allograft survival [17]. Our study represents
another step toward understanding transplantation ge-
nomics by examining multiple polymorphisms and events
simultaneously. The polygenic approach that we under-
took is by no means complete, however, and may have
excluded potentially significant genes involved in trans-
plantation.
CONCLUSION
Our data suggest that donor genetic heterogeneity has
a role in the assessment of donor risk factors and allograft
outcomes. Yet this conclusion is accompanied by certain
caveats. This particular donor population was skewed
toward Caucasians. Racial and ethnic groups demon-
strate alterations in expressions of certain polymorphisms
[26]. Therefore, it is imperative to note that multicen-
ter prospective studies that compile donors from vary-
ing racial and ethnic backgrounds will be necessary to
establish the validity of donor polymorphisms as impor-
tant transplant variables. Second, the data herein apply
only to kidney transplantation. It is possible that cer-
tain donor polymorphisms that have a negative impact
in kidneys could be beneficial in other organs. Finally,
the rate of biopsy-proven rejection in this donor popula-
tion is high. We purposely maintained the categorization
of rejection in relationship with the donor, given the in-
tent of the study. Even in shifting focus to the recipi-
ent number, this rate of biopsy-proven rejection remains
high. This could be possibly due to oversampling in this
population as there are more than 600 kidney transplant
biopsies, on average, per year at the University of Wis-
consin. Moreover, a confounding factor embedded in this
problem is the potential inability to adequately distin-
guish nonspecific inflammation from rejection with sim-
ply histologic assessment of the tissue. Such testing, while
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the subject of a number of reports and energetic exper-
imentation, is not yet perceived as a clinical standard.
Nonetheless, the study schema that we utilized with mul-
tiple genes and diverse outcome analyses sets the stage for
expanded prospective analyses of genomics in all forms
of transplantation. Moreover, it recognizes the simple but
significant fact that the allograft itself is an important
mediator and potential contributor to injury within its
environment.
ACKNOWLEDGMENTS
This work was supported in part by NIH grants 1RO1 AI-45925–
04 and 5K24 DK616962-02 (BNB). We thank the coordinators, nurses,
and staff of the University of Wisconsin Transplant Program and the
NIDDK Organ-Tissue Transplant Research Center for their efforts in
coordinating and providing clinical and research samples. We are appre-
ciative of the expert technical assistance provided by Seleem Sayaar and
Olivia Chang, and the statistical assistance provided by Roger Brown.
Reprint requests to Bryan N. Becker, M.D., 3034 Fish Hatchery Road,
UW Nephrology, Suite B, Madison, WI 53717.
E-mail: bnb@medicine.wisc.edu
REFERENCES
1. SANKARAN D, ASDERAKIS A, ASHRAF S, et al: Cytokine gene polymor-
phisms predict acute graft rejection following renal transplantation.
Kidney Int 56:281–288, 1999
2. ASDERAKIS A, SANKARAN D, DYER P, et al: Association of polymor-
phisms in the human interferon-gamma and interleukin-10 gene
with acute and chronic kidney transplant outcome: The cytokine
effect on transplantation. Transplantation 71:674–677, 2001
3. POLI F, BOSCHIERO L, GIANNONI F, et al: Tumour necrosis factor-
alpha gene polymorphism: Implications in kidney transplantation.
Cytokine 12:1778–1783, 2000
4. MARSHALL SE, MCLAREN AJ, HALDAR NA, et al: The impact of re-
cipient cytokine genotype on acute rejection after renal transplan-
tation. Transplantation 70:1485–1491, 2000
5. SIBBRING JS, SHARMA A, MCDICKEN IW, et al: Localization of C-
X-C and C-C chemokines to renal tubular epithelial cells in human
kidney transplants is not confined to acute cellular rejection. Transpl
Immunol 6:203–208, 1998
6. SUZUKI S, MIYAGI T, CHUANG LF, et al: Chemokine receptor CCR5:
Polymorphism at protein level. Biochem Biophys Res Commun
296:477–483, 2002
7. WOLFS TG, BUURMAN WA, VAN SCHADEWIJK A et al: In vivo expres-
sion of toll-like receptor 2 and 4 by renal epithelial cells: IFN-gamma
and TNF-alpha mediated up-regulation during inflammation. J Im-
munol 168:1286–1293, 2002
8. OTA T, TAMURA M, OSAJIMA A, et al: Expression of monocyte
chemoattractant protein-1 in proximal tubular epithelial cells in a
rat model of progressive kidney failure. J Lab Clin Med 140:43–51,
2002
9. HO RT, LIEW CT, LAI KN: The expression of hepatocyte growth
factor (HGF) and interleukin 6 (IL-6) in damaged human liver and
kidney tissues. Hepatogastroenterology 46:1904–1909, 1999
10. AIKAWA A, MCLAUGHLIN PJ, MCDICKEN IW, et al: TNF staining of
graft biopsies in renal transplantation. Transplantation 56:231–233,
1993
11. AIKAWA A, MCLAUGHLIN PJ, DAVIES HS, et al: TNF staining of graft
biopsy in renal transplantation. Transpl Int 5(Suppl 1):S651–652,
1992
12. LEE H, CLARK B, GOOI HC, et al: Influence of recipient and donor
IL-1alpha, IL-4, and TNFalpha genotypes on the incidence of acute
renal allograft rejection. J Clin Pathol 57:101–103, 2004
13. SEGERER S, BOHMIG GA, EXNER M, et al: When renal allografts turn
DARC. Transplantation 75:1030–1034, 2003
14. ANDERS HJ, VIELHAUER V, SCHLONDORFF D: Chemokines and
chemokine receptors are involved in the resolution or progression
of renal disease. Kidney Int 63:401–415, 2003
15. ST PETER SD, IMBER CJ, JONES DC, et al: Genetic determinants of
delayed graft function after kidney transplantation. Transplantation
74:809–813, 2002
16. MARSHALL SE, MCLAREN AJ, MCKINNEY EF, et al: Donor cytokine
genotype influences the development of acute rejection after renal
transplantation. Transplantation 71:469–476, 2001
17. BEIGE J, ENGELI S, RINGEL J, et al: Donor G protein beta3 subunit
825TT genotype is associated with reduced kidney allograft survival.
J Am Soc Nephrol 10:1717–1721, 1999
18. HOFFMANN SC, STANLEY EM, COX ED, et al: Ethnicity greatly influ-
ences cytokine gene polymorphism distribution. Am J Transplant
2:560–567, 2002
19. ABDI R, TRAN TB, SAHAGUN-RUIZ A, et al: Chemokine receptor
polymorphism and risk of acute rejection in human renal trans-
plantation. J Am Soc Nephrol 13:754–758, 2002
20. JACOBSEN P, TARNOW L, CARSTENSEN B, et al: Genetic variation in the
renin-angiotensin system and progression of diabetic nephropathy.
J Am Soc Nephrol 14:2843–2850, 2003
21. PRATSCHKE J, WILHELM MJ, LASKOWSKI I, et al: The influence of donor
brain death on long-term function of renal allotransplants in rats.
Transplant Proc 33:693–694, 2001
22. GASSER M, WAAGA AM, LASKOWSKI IA, TILNEY NL: The influence
of donor brain death on short and long-term outcome of solid organ
allografts. Ann Transplant 5:61–67, 2000
23. PRATSCHKE J, WILHELM MJ, LASKOWSKI I, et al: Influence of donor
brain death on chronic rejection of renal transplants in rats. J Am
Soc Nephrol 12:2474–2481, 2001
24. GOURISHANKAR S, JHANGRI GS, COCKFIELD SM, HALLORAN PF:
Donor tissue characteristics influence cadaver kidney transplant
function and graft survival but not rejection. J Am Soc Nephrol
14:493–499, 2003
25. HRICIK DE, RODRIGUEZ V, RILEY J, et al: Enzyme linked immunosor-
bent spot (ELISPOT) assay for interferon-gamma independently
predicts renal function in kidney transplant recipients. Am J Trans-
plant 3:878–884, 2003
26. HALLORAN PF, AFROUZIAN M, RAMASSAR V, et al: Interferon-gamma
acts directly on rejecting renal allografts to prevent graft necrosis.
Am J Pathol 158:215–226, 2001
27. WONG WK, ROBERTSON H, CARROLL HP, et al: Tubulitis in renal
allograft rejection: Role of transforming growth factor-beta and
interleukin-15 in development and maintenance of CD103+ in-
traepithelial T cells. Transplantation 75:505–514, 2003
28. EL-SAWY T, FAHMY NM, FAIRCHILD RL: Chemokines: Directing
leukocyte infiltration into allografts. Curr Opin Immunol 14:562–
568, 2002
29. INSTON NG, COCKWELL P: The evolving role of chemokines and
their receptors in acute allograft rejection. Nephrol Dial Transplant
17:1374–1379, 2002
30. SCHLONDORFF D, NELSON PJ, LUCKOW B, BANAS B: Chemokines and
renal disease. Kidney Int 51:610–621, 1997
31. SCHECTER AD, BERMAN AB, TAUBMAN MB: Chemokine receptors
in vascular smooth muscle. Microcirculation 10:265–272, 2003
32. AKALIN E, MURPHY B: Gene polymorphisms and transplantation.
Curr Opin Immunol 13:572–576, 2001
33. CARTWRIGHT NH, KEEN LJ, DEMAINE AG, et al: A study of cytokine
gene polymorphisms and protein secretion in renal transplantation.
Transpl Immunol 8:237–244, 2001
34. FISCHEREDER M, LUCKOW B, HOCHER B, et al: CC chemokine
receptor 5 and renal-transplant survival. Lancet 357:1758–1761,
2001
35. HAHN AB, KASTEN-JOLLY JC, CONSTANTINO DM, et al: TNF-alpha,
IL-6, IFN-gamma, and IL-10 gene expression polymorphisms and
the IL-4 receptor alpha-chain variant Q576R: Effects on renal allo-
graft outcome. Transplantation 72:660–665, 2001
36. POOLE KL, GIBBS PJ, EVANS PR, et al: Influence of patient and donor
cytokine genotypes on renal allograft rejection: Evidence from a
single centre study. Transpl Immunol 8:259–265, 2001
37. GANDHI N, GOLDMAN D, KAHAN D, et al: Donor cytokine gene poly-
morphisms are associated with increased graft loss and dysfunction
after transplant. Transplant Proc 33:827–828, 2001
